Influenza vaccine efficacy in patients aged 60–75 years in the 2016/2017 season

Background
From among the available and scientifically verified methods, vaccination every flu season is one of the most effective methods that aim at preventing flu, post-influenza complications and deaths. Its efficacy in preventing hospitalisation in patients over 65 years of age is 50–60%, and in preventing death from influenza and its complications, even up to 80%.

Objectives
The aim of the study was the assessment of influenza vaccine efficacy in patients aged 60–75 years in the 2016/2017 season

Material and methods
The study included 96 patients aged 60–75 years. BMI, as well as the initial level of haemagglutinin H1, H3, HB antibodies, were determined for all patients. All subjects were vaccinated with trivalent seasonal vaccine (Vaxigrip). In the period of 4–5 weeks after vaccination, the level of haemagglutinin H1, H3, HB antibodies was measured again in all patients.

Results
GMTs for all anti-haemagglutinins before and after vaccination differ significantly (p < 0.00001). The protection rate is higher after the vaccination than before for all anti-haemagglutinins, and these differences are statistically significant (p < 0.00001). In respect of each anti-haemagglutinin, the protection rate significantly exceeds the 60% threshold. The study showed proper immunogenicity of the influenza vaccine in the group of elderly people.

Conclusions
The influenza vaccination induces a proper immune response in patients aged 60–75, and therefore, it should be recommended in such patients as a form of effective protection against influenza and its complications